Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Helke who wrote (30007)	1/9/2000 1:32:00 PM
From: Henry Niman	Respond to of 32384

Although the therapies were approved, they were not approved for CTCL. The testimony indicated that the ability to do well controlled trials on a disease that affected a small population was very difficult, and there were far more failed trials than successful ones. I believe that there are only two drugs approved specifically for CTCL and they are both LGND's (ONTAK and oral Targretin). The patient population for CTCL is not only small, but very heterogeneous and although some patients are able to live with the disease for many years, I think that the recent FDA testimony indicated that in at least some cases (and I suspect many cases), living with the disease is far from ideal, and Targretin offers significant improvements, even if it does not produce a complete remission.